Literature DB >> 27189141

Systemic sclerosis.

Yannick Allanore1, Robert Simms2, Oliver Distler3, Maria Trojanowska2, Janet Pope4, Christopher P Denton5, John Varga6.   

Abstract

Systemic sclerosis is a complex autoimmune disease characterized by a chronic and frequently progressive course and by extensive patient-to-patient variability. Like other autoimmune diseases, systemic sclerosis occurs more frequently in women, with a peak of onset in the fifth decade of life. The exact cause of systemic sclerosis remains elusive but is likely to involve environmental factors in a genetically primed individual. Pathogenesis is dominated by vascular changes; evidence of autoimmunity with distinct autoantibodies and activation of both innate and adaptive immunity; and fibrosis of the skin and visceral organs that results in irreversible scarring and organ failure. Intractable progression of vascular and fibrotic organ damage accounts for the chronic morbidity and high mortality. Early and accurate diagnosis and classification might improve patient outcomes. Screening strategies facilitate timely recognition of life-threatening complications and initiation of targeted therapies to halt their progression. Effective treatments of organ-based complications are now within reach. Discovery of biomarkers - including autoantibodies that identify patient subsets at high risk for particular disease complications or rapid progression - is a research priority. Understanding the key pathogenetic pathways, cell types and mediators underlying disease manifestations opens the door for the development of targeted therapies with true disease-modifying potential. For an illustrated summary of this Primer, visit: http://go.nature.com/lchkcA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 27189141     DOI: 10.1038/nrdp.2015.2

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  190 in total

Review 1.  Interleukin-17: Friend or foe in organ fibrosis.

Authors:  Kritika Ramani; Partha S Biswas
Journal:  Cytokine       Date:  2019-02-14       Impact factor: 3.861

2.  Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis.

Authors:  Elena Pachera; Shervin Assassi; Gloria A Salazar; Mara Stellato; Florian Renoux; Adam Wunderlin; Przemyslaw Blyszczuk; Robert Lafyatis; Fina Kurreeman; Jeska de Vries-Bouwstra; Tobias Messemaker; Carol A Feghali-Bostwick; Gerhard Rogler; Wouter T van Haaften; Gerard Dijkstra; Fiona Oakley; Maurizio Calcagni; Janine Schniering; Britta Maurer; Jörg Hw Distler; Gabriela Kania; Mojca Frank-Bertoncelj; Oliver Distler
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

3.  Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis.

Authors:  Vivek Nagaraja; Marco Matucci-Cerinic; Daniel E Furst; Masataka Kuwana; Yannick Allanore; Christopher P Denton; Ganesh Raghu; Vallerie Mclaughlin; Panduranga S Rao; James R Seibold; John D Pauling; Michael L Whitfield; Dinesh Khanna
Journal:  Arthritis Rheumatol       Date:  2020-05-18       Impact factor: 10.995

Review 4.  The Primary Cilium: Emerging Role as a Key Player in Fibrosis.

Authors:  Maria E Teves; Jerome F Strauss; Paulene Sapao; Bo Shi; John Varga
Journal:  Curr Rheumatol Rep       Date:  2019-05-21       Impact factor: 4.592

5.  Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.

Authors:  Lucas C M Arruda; Kelen C R Malmegrim; João R Lima-Júnior; Emmanuel Clave; Juliana B E Dias; Daniela A Moraes; Corinne Douay; Isabelle Fournier; Hélène Moins-Teisserenc; Antônio José Alberdi; Dimas T Covas; Belinda P Simões; Pauline Lansiaux; Antoine Toubert; Maria Carolina Oliveira
Journal:  Blood Adv       Date:  2018-01-23

Review 6.  The perivascular origin of pathological fibroblasts.

Authors:  Selene E Di Carlo; Lucie Peduto
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

7.  Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.

Authors:  Katsunari Makino; Tomoko Makino; Lukasz Stawski; Julio C Mantero; Robert Lafyatis; Robert Simms; Maria Trojanowska
Journal:  J Invest Dermatol       Date:  2017-04-19       Impact factor: 8.551

Review 8.  An update on autoantibodies in scleroderma.

Authors:  Christopher A Mecoli; Livia Casciola-Rosen
Journal:  Curr Opin Rheumatol       Date:  2018-11       Impact factor: 5.006

9.  Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.

Authors:  Grettel García-Collinot; Eduardo Osiris Madrigal-Santillán; Michel A Martínez-Bencomo; Rosa A Carranza-Muleiro; Luis J Jara; Olga Vera-Lastra; Daniel H Montes-Cortes; Gabriela Medina; María Pilar Cruz-Domínguez
Journal:  Dig Dis Sci       Date:  2019-09-23       Impact factor: 3.199

10.  Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.

Authors:  Banafsheh Nazari; Lisa M Rice; Giuseppina Stifano; Alexander M S Barron; Yu Mei Wang; Tess Korndorf; Jungeun Lee; Jag Bhawan; Robert Lafyatis; Jeffrey L Browning
Journal:  Am J Pathol       Date:  2016-08-23       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.